CD40 or Bp50 is a member of the TNF receptor superfamily and a central regulator of anti-tumor immunity. Activation of CD40 on the cell surface of antigen presenting cells (APCs) promotes APCs ability to prime antigen-specific T cells and tumor-infiltrating myeloid cells thus enhancing their anti-tumor and anti-fibrotic activity . The ligand for CD40 is CD154, which is expressed on a variety of cell types, including activated T and B cells, endothelial and smooth muscle cells. CD40 is a promising target for cancer immunotherapy and CD40 activation in clinical trials demonstrated encouraging results in patients with pancreatic carcinoma, Hodgkin lymphoma, high-grade B cell lymphoma and metastatic melanoma.
|Tissue Type/Cancer Type|
0.5 mL – Manual – Concentrate, 1 mL – Manual – Concentrate, 6 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 100 Tests – Automation – i6000, 200 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual